303 related articles for article (PubMed ID: 32265836)
1. Determinants of the hCG Concentration in the Early Luteal Phase After Final Maturation of Follicles With Bolus Trigger of Recombinant hCG.
Vuong LN; Pham TD; Ho VNA; Ho TM; Humaidan P; Andersen CY
Front Endocrinol (Lausanne); 2020; 11():137. PubMed ID: 32265836
[No Abstract] [Full Text] [Related]
2. The early luteal hormonal profile in IVF patients triggered with hCG.
Vuong LN; Ho TM; Pham TD; Ho VNA; Andersen CY; Humaidan P
Hum Reprod; 2020 Jan; 35(1):157-166. PubMed ID: 31967304
[TBL] [Abstract][Full Text] [Related]
3. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
[TBL] [Abstract][Full Text] [Related]
4. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
5. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
[TBL] [Abstract][Full Text] [Related]
6. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
7. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
8. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
[TBL] [Abstract][Full Text] [Related]
9. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
[TBL] [Abstract][Full Text] [Related]
10. A drop in serum progesterone from oocyte pick-up +3 days to +5 days in fresh blastocyst transfer, using hCG-trigger and standard luteal support, is associated with lower ongoing pregnancy rates.
Uyanik E; Mumusoglu S; Polat M; Yarali Ozbek I; Esteves SC; Humaidan P; Yarali H
Hum Reprod; 2023 Feb; 38(2):225-236. PubMed ID: 36478179
[TBL] [Abstract][Full Text] [Related]
11. Response to ovulation trigger is correlated to late follicular phase progesterone levels: A hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise.
Friis Wang N; Skouby SO; Humaidan P; Andersen CY
Hum Reprod; 2019 May; 34(5):942-948. PubMed ID: 30927415
[TBL] [Abstract][Full Text] [Related]
12. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
[TBL] [Abstract][Full Text] [Related]
13. Hormonal profile in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients.
Martazanova B; Mishieva N; Vedikhina I; Kirillova A; Korneeva I; Ivanets T; Abubakirov A; Sukhikh GT
Front Endocrinol (Lausanne); 2022; 13():834627. PubMed ID: 36046787
[TBL] [Abstract][Full Text] [Related]
14. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
[TBL] [Abstract][Full Text] [Related]
15. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
[TBL] [Abstract][Full Text] [Related]
16. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
Gurbuz AS; Deveer R; Ozcimen N; Ozcimen EE; Lawrenz B; Banker M; Garcia-Velasco JA; Fatemi HM
Gynecol Endocrinol; 2016; 32(1):18-20. PubMed ID: 26487486
[TBL] [Abstract][Full Text] [Related]
17. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
[TBL] [Abstract][Full Text] [Related]
18. GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study.
Olgan S; Humaidan P
Reprod Biol; 2017 Mar; 17(1):105-110. PubMed ID: 28173995
[TBL] [Abstract][Full Text] [Related]
19. Multiple-dose versus single-dose gonadotropin-releasing hormone agonist after first in vitro fertilization failure associated with luteal phase deficiency: A randomized controlled trial.
Qu D; Li Y
J Int Med Res; 2020 Jun; 48(6):300060520926026. PubMed ID: 32495663
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
